Organization
Seoul National University College of Medicine
33 abstracts
1 poster
Abstract
Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: Primary results from the phase III NATALEE trial.Org: David Geffen School of Medicine at University of California Los Angeles, Moscow City Oncology Hospital No.62, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, National Taiwan University Hospital,
Abstract
Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study.Org: National Cancer Center Hospital Japan East, St. Marianna University School of Medicine, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, Seoul National University College of Medicine, HonorHealth Research Institute,
Abstract
First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).Org: Sackler School of Medicine, Hospital Universitario Fundación Jiménez Díaz, McGill University and MUHC, Sungkyunkwan University School of Medicine, Hospital Germans Trias i Pujol,
Abstract
Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL.Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul National University Hospital, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Department of Hematology-Oncology,
Abstract
ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC).Org: David Geffen School of Medicine at UCLA, University of California, Los Angeles, Seoul National University Hospital, Korea University Anam Hospital, Korea University College of Medicine,
Abstract
Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study.Org: Memorial Sloan Kettering Cancer Center, University of Vermont Cancer Center, Université Libre de Bruxelles (ULB), Institut Jules Bordet, Université Libre de Bruxelles, Medical Oncology Department,
Abstract
Long-term oncologic outcome of breast-conserving surgery in breast cancer with BRCA 1/2 mutation (ON-BRCA II, KoREa-BSG 06).Org: Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV, Dongtan Sacred Heart Hospital, Hallym University, Division of Breast Surgery, Samsung Medical Center,
Abstract
Patient-reported outcomes in N1 breast cancer: A phase III trial comparing whole-breast to whole-breast plus regional irradiation after taxane-based chemotherapy (KROG 1701).Org: Samsung Medical Center, Chonnam National University Medical School and CNU Hwasun Hospital, Asan Medical Center, Soonchunhyang University Hospital, Gil Medical Center,
Abstract
Personalized neoadjuvant strategy in ER positive and HER2 negative breast cancer to increase BCS rate (PLATO): A prospective, multicenter, phase II clinical trial.Org: Seoul National University Hospital, Seoul National University College of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul National University Bundang Hospital,
Abstract
Genomic landscape and therapeutic implications in advanced solid cancers: KOSMOS-II (KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors, KCSG AL-22-09).Org: Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, National Cancer Center Hospital East, Kashiwa, Japan, Goyang-Si, South Korea, Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy,
Abstract
Effect of a learning-based approach using the echo-signals obtained by a single-unit transducer on detection of breast tumors.Org: L'imagin Inc, Seoul National University Hospital, Seoul National University College of Medicine, Department of Transdisciplinary Medicine, Seoul Metropolitan Government Seoul National University,
Abstract
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study.Org: Institut Català D'Oncologia, IDIBELL, Seoul National University Hospital, Cancer Research Institute, Aichi Cancer Center Hospital,
Abstract
A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer.Org: National Cancer Center Hospital East, Chiba, Japan, Samsung Medical Center, Seoul, seoul, South Korea, NEXT Oncology, San Antonio, TX, National Cancer Center Hospital, Tokyo, Japan, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea,
Abstract
Detection of contralateral breast cancer in patients with primary breast cancer through AI-assisted mammography.Org: Department of Surgery, Brigham and Women's Hospital, Boston, MA, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea,
Abstract
Lorlatinib in TKI naïve, advanced ROS1-positive non-small-cell lung cancer: A multicenter, open-label, single-arm, phase 2 trial.Org: Center for Lung Cancer, Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Research Institute and Hospital, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
A phase 1 study of AT101, a novel anti-CD19 CAR-T cell therapy targeting a membrane-proximal epitope of CD19, in patients with relapsed or refractory B cell non-Hodgkin lymphoma.Org: Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, Ulsan University Hospital, Ulsan, South Korea,
Abstract
Artificial intelligence–powered tumor-infiltrating lymphocytes analyzer to reveal distinct immune landscapes in breast cancer by molecular subtype and HER2 score.Org: Oncology Therapeutic Development, Lunit Inc., Samsung Medical Center, Sungkyunkwan University School of Medicine, Kyung Hee University Hospital,
Abstract
Olaparib (O) + ceralasertib (C) in patients (pts) with metastatic triple-negative breast cancer (mTNBC): Translational analysis of the VIOLETTE trial.Org: AstraZeneca, University Hospitals Leuven, Leuven, Belgium, The Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Seoul National University College of Medicine, Christie Hospital NHS Foundation Trust and the University of Manchester,
Abstract
The metabolic activity assessed by 18F-FDG PET and its correlation with tumor immune status and prognosis in advanced biliary tract cancer patients treated with 1L GemCis plus durvalumab +/-tremelimumab.Org: Medical Oncology Group, Seoul National University Hospital, Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,
Abstract
INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–) PIK3CA‑mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Winship Cancer Center of Emory University, Seoul National University Hospital, Cancer Research Institute,
Abstract
Omission of breast surgery for predicted pCR patients with MRI and vacuum-assisted biopsy in breast cancer after neoadjuvant chemotherapy: A multicenter, single-arm, non-inferiority trial (OPTIMIST trial).Org: Department of Surgery, Brigham and Women's Hospital, Boston, MA, Seoul National University College of Medicine, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Seoul National University Hospital, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
Prospective single-arm study of endocrine therapies with ovarian function suppression in premenopausal patients with node-positive early breast cancer with low genomic risk (INTERSTELLAR trial, KBCSG-25).Org: Gangnam Severance Hospital, Yonesi University College of Medicine, Gangnam-Gu, Nacuity Pharmaceuticals, Korea United Pharmaceuticals Inc.,
Abstract
Impact of distance between tumor and nipple on survival outcomes in breast cancer.Org: Department of Surgery, Brigham and Women's Hospital, Boston, MA, Seoul Metropolitan Government Seoul National University, Boramae Medical Center, Seoul, South Korea, Seoul National University College of Medicine,
Abstract
Comprehensive geriatric assessment based multidisciplinary team intervention for hospitalized frail patients in oncology: COMPASS-ONCO/KCSG AL21-13.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, Division of Hematology/Oncology, Department of Medicine, University Of Toledo,
Abstract
Investigating the novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager, AFM24, to leverage the innate immune system: Interim results from the colorectal cancer (CRC) cohort.Org: INCLIVA-Biomedical Research Institute, Biomedical Research Institute INCLIVA, Hospital Clínico Universitario-INCLIVIA, Valencia, Spain, University of Valencia, Affimed Inc.,
Abstract
Sustained prognostic impact of primary tumor characteristics on long-term (overall) survival after distant metastasis in young ER+ HER2- breast cancer.Org: Department of Surgery, Brigham and Women's Hospital, Boston, MA, Dongtan Sacred Heart Hospital, Hallym University, Seoul National University College of Medicine, Samsung Medical Center,
Abstract
Comprehensive genomic analysis for homologous recombination deficiency in pancreatic cancer.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea,
Abstract
Whole genome sequencing for more accurate TMB and mutational signatures in common cancers.Org: Genome Insight Inc., Ajou University School of Medicine, Genome Insight, San Diego, CA, Seoul National University College of Medicine, Seoul National University Hospital,
Abstract
Impact of postoperative residual disease in patients with primary epithelial ovarian cancer in the era of maintenance therapies with targeted agents: A systematic review and meta-analysis.Org: National Cancer Center Korea, Seoul National University College of Medicine, National Cancer Center Hospital East, Kashiwa, Japan, Pusan National University Yangsan Hospital, Seoul National University Hospital,
Abstract
Response monitoring with ctDNA in metastatic pancreatic cancer.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul National University Hospital,
Abstract
Cost-effective analysis of rotational intraperitoneal aerosol chemotherapy (RIPAC) in patients with platinum-resistant ovarian cancer.Org: Seoul National University Hospital, Seoul National University College of Medicine,
Abstract
Integrated clinico-genomic characterization of pancreatic ductal adenocarcinoma in an Asian population.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea,
Abstract
One way to provide effective healthcare services for patients with advanced cancer to improve their quality of life and survival: Prediction modeling using machine learning techniques and causal relationship between self-management strategy, health-related quality of life, and survival.Org: Seoul National University College of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Ulsan Univ Hosp, Univ of Ulsan,